J3473
J3473 – Injection, hyaluronidase, recombinant, 1 usp unit · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked per 1 USP UNIT $0.364/unit ASP+6%
📋 J3473 summary
J3473 is a HCPCS Level II J-code used to bill hyaluronidase, recombinant, 1 usp unit, billed per 1 USP UNIT. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J3473: Hylenex, Hylenex Recombinant, Hyaluronidase
Code J3473
Billing unit 1 USP UNIT Payment limit $0.364/unit NDC-Crosswalk 2
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ3473
DescriptorInjection, hyaluronidase, recombinant, 1 usp unit
Billing unit1 USP UNIT
Payment limit / unit$0.364
Est. ASP / unit$0.343 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.364
Est. ASP / unit
$0.343 est.
Est. after 2% sequester
$0.357
HCPCS dosage
1 USP UNIT
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, hyaluronidase, recombinant, 1 usp unit
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2007-01-01
Date added2007-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J3473 = 1 usp. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J3473 LEAST EXPENSIVE FIRST
2 NDCs map to J3473. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.364/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 18657-0117-04 | HYLENEX Recombinant Hyaluronidase 150 [USP'U]/mL INJECTION, SOLUTION | Antares | 4 BOX in 1 CARTON (18657-117-04) / 1 VIAL... | 150 [USP'U]/mL | 600 | $218.40 | $53.705 | ● Active | CMS + PDAC |
| 51662-1555-01 | HYALURONIDASE 150 [USP'U]/mL INJECTION, SOLUTION | HF | 1 VIAL in 1 BOX (51662-1555-1) / 1 mL in... | 150 [USP'U]/mL | 150 | $54.60 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$6K
Claims
109
Beneficiaries
101
Spend / beneficiary
$59.56
Spend / claim
$55.19
Trend by period
Where J3473 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #705 of 824
#700
PROGRAF(J7525)* J7525
$6.4K
#701
IBANDRONATE SODIUM J1740
$6.3K
#702
LEVOLEUCOVORIN CALCI... J0641
$6.2K
#703
PREMARIN J1410
$6.2K
#704
ORPHENADRINE CITRATE J2360
$6.1K
#705
HYLENEX J3473
$6K
#706
NOVACHOR 1 SQ CM** Q4194
$5.7K
#707
MITOXANTRONE HCL J9293
$5.6K
#708
NEBUPENT(J2516)* J2516
$5.4K
#709
CALCIUM GLUCONATE-NA... J0612
$5.2K
#710
DELESTROGEN* J1380
$5.1K
Total claims — #622 of 824
#617
NOVOSEVEN RT J7189
114
#618
FLUDARABINE PHOSPHAT... J9185
113
#619
MARGENZA J9353
112
#620
SIMULECT J0480
109
#621
CEFUROXIME SODIUM J0697
109
#622
HYLENEX J3473
109
#623
COCOON MEMBRANE, PER... Q4264
109
#624
BYOOVIZ Q5124
109
#625
ACYCLOVIR SODIUM J0133
108
#626
ORBACTIV J2407
108
#627
EDETATE CALCIUM DISO... J0600
107
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $6K | 101 | 109 | $59.56 | $55.19 |
| 2025 (Q1-Q4) | $28.1K | 401 | 456 | $70.07 | $61.62 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$30.3K
Medicare paid
$20K
Submitted services
131,302
Denial rate
36.5%
Allowed / service
$0.36
Submitted charges
$247.9K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J3473 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 130,200 services across 3 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J3473
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J3473 billing FAQ
What is HCPCS code J3473?
J3473 is a HCPCS Level II J-code used to bill Injection, hyaluronidase, recombinant, 1 usp unit under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J3473?
One unit of J3473 represents 1 USP UNIT. Report the number of units equal to the dose administered divided by 1 USP UNIT.
How many units of J3473 should I bill?
Divide the dose administered by the code's unit size (1 USP UNIT) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J3473?
The Medicare Part B payment limit is $0.364 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.357 per unit. Payment limits are revised quarterly.
Which NDCs bill under J3473?
2 NDCs currently map to J3473 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J3473 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.